- Trials with a EudraCT protocol (22)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
22 result(s) found for: Digital rectal examination.
Displaying page 1 of 2.
EudraCT Number: 2018-004758-39 | Sponsor Protocol Number: ESR-18-13485 | Start Date*: 2019-06-12 | |||||||||||
Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA | |||||||||||||
Full Title: A PHASE II STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AS PREOPERATIVE TREATMENT IN RECTAL CANCER | |||||||||||||
Medical condition: Locally advanced (T3-4 N0-1) rectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003933-33 | Sponsor Protocol Number: 12K3-S-140708 | Start Date*: 2006-12-20 |
Sponsor Name:Bundeswehr | ||
Full Title: Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer | ||
Medical condition: Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer referring to histopathological, pos... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001387-28 | Sponsor Protocol Number: NL73559.091.20 | Start Date*: 2020-06-22 | ||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||
Full Title: 18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathology. | ||||||||||||||||||
Medical condition: 75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018311-15 | Sponsor Protocol Number: GE-148-003 | Start Date*: 2010-05-21 |
Sponsor Name:GE Healthcare Limited | ||
Full Title: A Phase 2, Open-label Study to Assess the Uptake and Retention and Safety of GE 148 (18F) Injection in Subjects with Biopsy-proven Prostate Cancer who are Scheduled for Radical Prostatectomy | ||
Medical condition: Detection of abnormal amino acid transport using Positron Emission Tomography (PET) in malignancy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023083-40 | Sponsor Protocol Number: SPON830-10 | Start Date*: 2012-03-19 |
Sponsor Name:Cardiff University | ||
Full Title: A Phase II study of neoadjuvant chemotherapy given before SCPRT as treatment for patients with MRI-staged operable rectal cancer at high risk of metastatic relapse | ||
Medical condition: Rectal adenocarcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-000222-38 | Sponsor Protocol Number: P00048GP404 | Start Date*: 2014-06-03 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: PERMIXON® 160 mg hard capsule versus placebo in the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia. Single-blind placebo run-in period then double-blin... | |||||||||||||
Medical condition: PERMIXON® 160 mg hard capsule versus placebo in the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) CZ (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004672-35 | Sponsor Protocol Number: 09-025 | Start Date*: 2014-05-13 | ||||||||||||||||
Sponsor Name:Cook Myosite, Incorporated | ||||||||||||||||||
Full Title: A Prospective Nonrandomized Study of Autologous Muscle Derived cell (AMDC) Transplantation for Treatment of Fecal Incontinence | ||||||||||||||||||
Medical condition: Fecal incontinence in men and women | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-000848-83 | Sponsor Protocol Number: CSO181 | Start Date*: 2005-07-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Consumer Healthcare GmbH & Co KG, 77815 Bühl | |||||||||||||
Full Title: Teilverblindete, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Wirksamkeit von Dickextrakt aus Kürbissamen (Kürbissamen-Extrakt) und Kürbissamen bei Patienten mit benigner Prosta... | |||||||||||||
Medical condition: benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003740-39 | Sponsor Protocol Number: URO-CHUAC-BPSat-001. | Start Date*: 2016-04-12 | |||||||||||
Sponsor Name:Jose Luis Ponce Díaz-Reixa | |||||||||||||
Full Title: Open randomized clinical trial to examine individual pain tolerance in the use of two anesthetic techniques to perform saturation prostate biopsy . | |||||||||||||
Medical condition: Prostate biopsy anesthesia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003792-19 | Sponsor Protocol Number: FOS-PROST-001 | Start Date*: 2021-03-04 |
Sponsor Name:Hospital Universitari Mutua Terrassa | ||
Full Title: Fosfomycin as an oral alternative treatment for acute bacterial prostatitis due to multi-drug resistant Escherichia coli. Pilot study | ||
Medical condition: Acute bacterial prostatitis due to multi-drug resistant Escherichia coli | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000245-12 | Sponsor Protocol Number: Repha_1436 | Start Date*: 2020-01-20 | ||||||||||||||||
Sponsor Name:Repha GmbH | ||||||||||||||||||
Full Title: Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type ir... | ||||||||||||||||||
Medical condition: A confirmed diagnosis of irritable bowel syndrome (IBS-D or IBS-M) by a specialist in gastroenterology and/or internal medicine and/or general medicine | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000154-76 | Sponsor Protocol Number: BXL628 02 14 | Start Date*: 2005-03-16 | |||||||||||
Sponsor Name:BIOXELL SPA | |||||||||||||
Full Title: A randomized, double blind, double dummy, placebo controlled, parallel group study to determine the effect of BXL628 in monotherapy 75 mcg and 150 mcg and in combination 150 mcg with tamsulosi... | |||||||||||||
Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003523-16 | Sponsor Protocol Number: ARN-I-20-DEU-003-V01 | Start Date*: 2021-12-29 |
Sponsor Name:Universität des Saarlandes | ||
Full Title: A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer | ||
Medical condition: patients with locally advanced T4 high risk prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001903-10 | Sponsor Protocol Number: OX51-002 | Start Date*: 2012-08-07 | |||||||||||
Sponsor Name:Orexo AB | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, dose finding trial using sublingual alfentanil to alleviate pain associated with a prostate biopsy procedure | |||||||||||||
Medical condition: Pain associated with prostate biopsy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FI (Completed) CZ (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002276-37 | Sponsor Protocol Number: AK-2017-PC-1 | Start Date*: 2017-08-25 | |||||||||||
Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET | |||||||||||||
Full Title: Phase II trial: uPAR-PET/MR in patients with newly diagnosed prostate cancer; non-invasive characterization of tumor aggressiveness | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003165-15 | Sponsor Protocol Number: FACBC-STAGING-2014 | Start Date*: 2014-12-02 | |||||||||||
Sponsor Name:AOU di Bologna Policlinico S.Orsola-Malpighi | |||||||||||||
Full Title: 18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER | |||||||||||||
Medical condition: Patients affected by moderate to high risk primary prostate cancer who are scheduled for surgery with a planned, elective lymph node dissection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005315-26 | Sponsor Protocol Number: A25165 | Start Date*: 2008-07-01 | |||||||||||
Sponsor Name:CONRAD, Eastern Virgina Medical School | |||||||||||||
Full Title: Sperm Suppression and Contraceptive Protection provived by Norethisterone Enantate (NET-EN) combined with Testosterone Undecanoate (TU) in healthy men. | |||||||||||||
Medical condition: The proposed study is designed to evaluate whether the combination of a progestin, norethisterone enantate (NET-EN), and an androgen, testosterone undecanoate (TU), represents a safe and effective ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Temporarily Halted) GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002484-15 | Sponsor Protocol Number: AMW/004/C | Start Date*: 2015-12-14 | |||||||||||
Sponsor Name:AMW GmbH | |||||||||||||
Full Title: An open label, multiple dose, Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy of AMW goserelin 3.6 mg implant in its application system | |||||||||||||
Medical condition: prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005307-33 | Sponsor Protocol Number: P00048GP403 | Start Date*: 2012-09-24 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multi... | |||||||||||||
Medical condition: The aim of the proposed study is to assess the activity on inflammation biomarkers of L.S.E.S.r (PERMIXON® 160mg hard capsule) and Tamsulosine LP in the treatment of BPH. The potential links betwee... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006674-22 | Sponsor Protocol Number: 56021927PCR2046 | Start Date*: 2022-12-12 | |||||||||||
Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s. | |||||||||||||
Full Title: AD ASTRA (Androgen Deprivation with Apalutamide and STereotactic RAdiotherapy) Prospective institutional phase II study of efficacy and safety of androgen deprivation with apalutamide in high-risk ... | |||||||||||||
Medical condition: Localized or a locally advanced high-risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
